ALIMERA SCIENCES INC Uncategorized Contracts & Agreements
55 Contracts & Agreements
- Alimera Sciences, Inc. 2024 Equity Inducement Plan (Filed With SEC on February 9, 2024)
- Omnibus Exit Fee Agreement dated as of May 17, 2023, by and among Alimera Sciences, Inc., SLR Investment Corp., as Collateral Agent, and the parties signatory thereto as Lenders,... (Filed With SEC on August 11, 2023)
- Chairman Emeritus Agreement, dated as of August 1, 2023 by and between Alimera Sciences, Inc. and C. Daniel Myers (Filed With SEC on August 2, 2023)
- Description of Securities (Filed With SEC on March 23, 2022)
- Description of Securities (Filed With SEC on March 5, 2021)
- Description of Securities (Filed With SEC on March 2, 2020)
- Exit Fee Agreement dated as of December 31, 2019, by and among Alimera Sciences, Inc., Solar Capital Ltd. as collateral agent, and the Lenders (Filed With SEC on January 6, 2020)
- Form of Alimera Sciences, Inc. Deduction Agreement (Filed With SEC on September 5, 2019)
- Exit Fee Agreement dated as of January 5, 2018 by and among Alimera Sciences, Inc., Solar Capital Ltd. as collateral agent, and the Lenders (Filed With SEC on January 8, 2018)
- CONFIDENTIAL TREATMENT REQUESTED (Filed With SEC on May 6, 2016)
- EXHIBIT 10.41 CONFIDENTIAL TREATMENT REQUESTED (Filed With SEC on March 28, 2013)
- Interim Condensed Consolidated Financial Statements (unaudited) (Filed With SEC on August 14, 2012)
- EX-101 INSTANCE DOCUMENT (Filed With SEC on August 5, 2011)
- delay in or failure to obtain regulatory approval of the Companys product candidates (Filed With SEC on March 25, 2011)
- delay in or failure to obtain regulatory approval of the Companys product candidates (Filed With SEC on March 25, 2011)
- Entry into a Definitive Material Agreement (Filed With SEC on October 18, 2010)
- Entry into a Definitive Material Agreement (Filed With SEC on October 18, 2010)
- Entry into a Definitive Material Agreement (Filed With SEC on October 18, 2010)
- Entry into a Definitive Material Agreement (Filed With SEC on October 18, 2010)
- CONFIDENTIAL TREATMENT REQUESTED COMMERCIAL CONTRACT MANUFACTURING AGREEMENT Dated as of February 5, 2010 By and Between Alimera Sciences, Inc. And Alliance Medical Products, Inc. (Filed With SEC on March 19, 2010)
- Pursue FDA Approval for Iluvien. In December 2009 we received the month 24 clinical readout from our FAME Study. Based upon our analysis of this data, we plan to file an NDA in... (Filed With SEC on March 15, 2010)
- Pursue FDA Approval for Iluvien. In December 2009 we received the month 24 clinical readout from our FAME Study. Based upon our analysis of this data, we plan to file an NDA in... (Filed With SEC on March 15, 2010)
- Pursue FDA Approval for Iluvien. In December 2009 we received the month 24 clinical readout from our FAME Study. Based upon our analysis of this data, we plan to file an NDA in... (Filed With SEC on December 23, 2009)
- Pursue FDA Approval for Iluvien. In December 2009 we received the month 24 clinical readout from our FAME Study. Based upon our analysis of this data, we plan to file an NDA in... (Filed With SEC on December 23, 2009)
- Pursue FDA Approval for Iluvien. In December 2009 we received the month 24 clinical readout from our FAME Study. Based upon our analysis of this data, we plan to file an NDA in... (Filed With SEC on December 23, 2009)
- Pursue FDA Approval for Iluvien. In December 2009 we received the month 24 clinical readout from our FAME Study. Based upon our analysis of this data, we plan to file an NDA in... (Filed With SEC on December 23, 2009)
- Pursue FDA Approval for Iluvien. In December 2009 we received the month 24 clinical readout from our FAME Study. Based upon our analysis of this data, we plan to file an NDA in... (Filed With SEC on December 23, 2009)
- Pursue FDA Approval for Iluvien. In December 2009 we received the month 24 clinical readout from our FAME Study. Based upon our analysis of this data, we plan to file an NDA in... (Filed With SEC on December 23, 2009)
- Pursue FDA Approval for Iluvien. In December 2009 we received the month 24 clinical readout from our FAME Study. Based upon our analysis of this data, we plan to file an NDA in... (Filed With SEC on December 23, 2009)
- Pursue FDA Approval for Iluvien. In December 2009 we received the month 24 clinical readout from our FAME Study. Based upon our analysis of this data, we plan to file an NDA in... (Filed With SEC on December 23, 2009)
- Pursue FDA Approval for Iluvien. In December 2009 we received the month 24 clinical readout from our FAME Study. Based upon our analysis of this data, we plan to file an NDA in... (Filed With SEC on December 23, 2009)
- Pursue FDA Approval for Iluvien. In December 2009 we received the month 24 clinical readout from our FAME Study. Based upon our analysis of this data, we plan to file an NDA in... (Filed With SEC on December 23, 2009)
- Pursue FDA Approval for Iluvien. In December 2009 we received the month 24 clinical readout from our FAME Study. Based upon our analysis of this data, we plan to file an NDA in... (Filed With SEC on December 23, 2009)
- Pursue FDA Approval for Iluvien. In December 2009 we received the month 24 clinical readout from our FAME Study. Based upon our analysis of this data, we plan to file an NDA in... (Filed With SEC on December 23, 2009)
- Pursue FDA Approval for Iluvien. In December 2009 we received the month 24 clinical readout from our FAME Study. Based upon our analysis of this data, we plan to file an NDA in... (Filed With SEC on December 23, 2009)
- Pursue FDA Approval for Iluvien. In December 2009 we received the month 24 clinical readout from our FAME Study. Based upon our analysis of this data, we plan to file an NDA in... (Filed With SEC on December 23, 2009)
- Pursue FDA Approval for Iluvien. In December 2009 we received the month 24 clinical readout from our FAME Study. Based upon our analysis of this data, we plan to file an NDA in... (Filed With SEC on December 23, 2009)
- Pursue FDA Approval for Iluvien. In the fourth quarter of 2009 we will receive a month 24 readout from the FAME Study. Based on an analysis of this readout we plan to pursue an... (Filed With SEC on October 30, 2009)
- Pursue FDA Approval for Iluvien. In the fourth quarter of 2009 we will receive a month 24 readout from the FAME Study. Based on an analysis of this readout we plan to pursue an... (Filed With SEC on October 30, 2009)
- Pursue FDA Approval for Iluvien. In the fourth quarter of 2009 we will receive a month 24 readout from the FAME Study. Based on an analysis of this readout we plan to pursue an... (Filed With SEC on October 30, 2009)
